OK HB2801

Oklahoma Health Care Authority must approve prior authorization requests for FDA-approved atypical antipsychotics not on the preferred drug list for treating mood disorders with psychotic symptoms, bipolar disorders, schizophrenia, and schizotypal or delusional disorders

Approval requires either a trial and failure of any preferred atypical antipsychotic within the preceding 365 days, or documentation that the patient is stable on a non-preferred atypical antipsychotic

Non-preferred atypical antipsychotics must be available at parity with other branded medications in the same class

Approval can be based on patient claims history or health care provider attestation of qualifying conditions

Effective date: November 1, 2025